In CRC, EGFR signaling plays a central role and, as a notable exception among targeted therapies, EGFR inhibition is beneficial even when EGFR is genetically intact, provided the downstream RAS pathway is not oncogenically activated [47, 48]. This evidence concerns the gene EGFR and colorectal carcinoma.